| Patents for A61P 25 - Drugs for disorders of the nervous system (183,225) |
|---|
| 01/15/2004 | CA2491464A1 Process for preparation of 1,3-benzodioxole-2-spiro- cycloalkane derivatives |
| 01/15/2004 | CA2491455A1 Novel use of imidazotriazinones |
| 01/15/2004 | CA2491451A1 Novel pharmaceutical compositions comprising novel anticholinergic agents and nk1-receptor antagonists |
| 01/15/2004 | CA2491445A1 Compositions and methods for reduction of inflammatory symptoms and/or biomarkers in female subjects |
| 01/15/2004 | CA2491406A1 Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs |
| 01/15/2004 | CA2491286A1 Methods of screening compounds for grk6 modulating activity |
| 01/15/2004 | CA2491132A1 Estrieno[3,2-b]/[3,4-c]pyrrole derivatives useful as modulators of the estrogen receptors |
| 01/15/2004 | CA2491127A1 Nitrosated nonsteroidal antiinflammatory compounds, compositions and methods of use |
| 01/15/2004 | CA2490714A1 Use of alanyl-aminopeptidase inhibitors and pharmaceutical compositions containing said inhibitors |
| 01/15/2004 | CA2490707A1 Method of using ryanodine antagonists in treating neural injury |
| 01/15/2004 | CA2490494A1 Pkc activation as a means for enhancing sapp.alpha. secretion and improving cognition using bryostatin type compounds |
| 01/15/2004 | CA2490463A1 1-amido-4-phenyl-4-benzyloxymethyl-piperidine derivatives and related compounds as neurokinin-1(nk-1) antagonists for the treatment of emesis, depression, anxiety and cough |
| 01/15/2004 | CA2490097A1 Di-aryl-substituted-ethane pyridone pde4 inhibitors |
| 01/15/2004 | CA2489754A1 .beta.-sheet breaking peptides |
| 01/15/2004 | CA2489572A1 Extended-release tablets comprising divalproex sodium |
| 01/15/2004 | CA2489396A1 Utilization of heteroarene carboxamide as dopamine-d3 ligands for the treatment of cns diseases |
| 01/15/2004 | CA2488736A1 Use of cetp inhibitors and optionally hmg coa reductase inhibitors and/or antihypertensive agents |
| 01/15/2004 | CA2485379A1 Secondary amino anilinic piperidines as mch1 antagonists and uses thereof |
| 01/15/2004 | CA2460051A1 7,8,9,10-tetrahydro-6h-azepino, 6,7,8,9-tetrahydro-pyrido and 2,3-dihydro-2h-pyrrolo[2,1-b]-quinazolinone derivatives |
| 01/14/2004 | EP1380594A1 Fibroblast growth factor-10 |
| 01/14/2004 | EP1380593A1 Soluble rage protein |
| 01/14/2004 | EP1380576A1 Novel 1h-indazole compound |
| 01/14/2004 | EP1380573A2 Isoquinolines and preparation thereof |
| 01/14/2004 | EP1380562A1 Carboxylic acid derivative and salt thereof |
| 01/14/2004 | EP1380306A1 Remedies for psychoneurosis |
| 01/14/2004 | EP1380296A1 Hsp inductor |
| 01/14/2004 | EP1380292A1 Tiaprid for the treatment of depressions |
| 01/14/2004 | EP1380291A1 PDE IV inhibitors for treating multiple sclerosis |
| 01/14/2004 | EP1380290A1 Cross-beta structure pathway and its therapeutic relevance |
| 01/14/2004 | EP1379882A1 Diagnostic and therapeutic use of a nuclear restricted protein for alzheimer's disease and related neurodegenerative disorders |
| 01/14/2004 | EP1379880A2 Screening for drugs against disorders associated with schizophrenia |
| 01/14/2004 | EP1379695A2 New polynucleotides and polypeptides of the ifnalpha-21 gene |
| 01/14/2004 | EP1379694A2 Methods, systems and computer program products for determining the biological effect and/or activity of drugs, chemical substances and/or pharmaceutical compositions based on their effect on the methylation status of the dna |
| 01/14/2004 | EP1379672A2 Chimeric molecules containing a module able to target specific cells and a module regulating the apoptogenic function of the permeability transition pore complex (ptpc) |
| 01/14/2004 | EP1379654A2 Intracellular signaling molecules |
| 01/14/2004 | EP1379652A2 Human nucleic acid molecules and polypeptides encoding a human ion channel expressed in spinal cord and brain |
| 01/14/2004 | EP1379650A2 Preferred segments of neural thread protein and methods of using the same |
| 01/14/2004 | EP1379649A2 Calcium binding proteins |
| 01/14/2004 | EP1379648A1 Full-length human cdnas encoding potentially secreted proteins |
| 01/14/2004 | EP1379628A2 Kinases and phosphatases sequences, and use thereof |
| 01/14/2004 | EP1379627A1 Method for differentiating mesenchymal stem cells into neural cells |
| 01/14/2004 | EP1379624A2 Transfection of human embryonic stem cells |
| 01/14/2004 | EP1379557A2 Use of cd25 binding molecules in steroid-resistant patients |
| 01/14/2004 | EP1379546A2 Peptide for the diagnosis and therapy of alzheimer's disease |
| 01/14/2004 | EP1379542A2 Treatment of tumours |
| 01/14/2004 | EP1379528A1 Pyrazolopyrimidines as therapeutic agents |
| 01/14/2004 | EP1379525A2 Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists |
| 01/14/2004 | EP1379524A2 Chromane derivatives, process for their preparation and their use as antitumor agents |
| 01/14/2004 | EP1379523A1 1,2,3,4-tetrahydroisoquinolines derivatives as urotensin ii receptor antagonists |
| 01/14/2004 | EP1379522A1 DIHYDRO-BENZO(b)(1,4)DIAZEPIN-2-ONE DERIVATIVES AS MGLUR2 ANTAGONISTS I |
| 01/14/2004 | EP1379520A1 N-substituted nonaryl-heterocyclic nmda/nr2b antagonists |
| 01/14/2004 | EP1379519A1 Pyrrolidine sulfonamides |
| 01/14/2004 | EP1379516A1 Alkoxycarbonylamino benzoic acid or alkoxycarbonylamino tetrazolyl phenyl derivatives as ip antagonists |
| 01/14/2004 | EP1379514A2 5-membered heterocycles, preparation and application thereof as medicaments |
| 01/14/2004 | EP1379513A1 Prodrugs of cox-2 inhibitors |
| 01/14/2004 | EP1379511A1 DIHYDRO-BENZO (b) (1, 4) DIAZEPIN-2-ONE DERIVATIVES AS MGLUR2 ANTAGONISTS II |
| 01/14/2004 | EP1379508A2 N-(aryl)-2-arylethenesulfonamides and therapeutic uses thereof |
| 01/14/2004 | EP1379507A1 HETEROARYL UREAS CONTAINING NITROGEN HETERO-ATOMS AS p38 KINASE INHIBITORS |
| 01/14/2004 | EP1379504A1 Bipiperidinyl-derivatives and their use as chemokine receptors inhibitors |
| 01/14/2004 | EP1379503A1 Pyrrolidine sulfonamides |
| 01/14/2004 | EP1379502A1 Nicotinic acetylcholine receptor ligands |
| 01/14/2004 | EP1379498A1 Sulphones which modulate the action of gamma secretase |
| 01/14/2004 | EP1379496A1 Sulphones which modulate the action of gamma secretase |
| 01/14/2004 | EP1379495A2 Ligands of the alpha-v-beta 6 integrin |
| 01/14/2004 | EP1379494A1 Fused bicyclic or tricyclic amino acids |
| 01/14/2004 | EP1379493A2 Non-imidazole aryl alkylamines compounds as histamine h3 receptor antagonists, preparation and therapeutic uses |
| 01/14/2004 | EP1379492A1 Inhibitor of monoamine uptake |
| 01/14/2004 | EP1379283A2 Identification of target-specific folding sites in peptides and proteins |
| 01/14/2004 | EP1379282A2 Methods and compositions for the treatment and/or diagnosis of neurological diseases and disorders |
| 01/14/2004 | EP1379279A1 Orally deliverable pharmaceutical composition comprising a drug of low water solubility (cox-2 inhibitor), a solvent, a fatty acid and an organic amine |
| 01/14/2004 | EP1379269A1 Adenosine a2a receptor antagonists combined with neurotrophic activity compounds in the treatment of parkinson's disease |
| 01/14/2004 | EP1379262A1 Method for preparing an extract of ginkgo biloba leaves highly enriched in active principles |
| 01/14/2004 | EP1379261A2 Method for increasing serotonin levels in a person by administration of a composition incorporating (-)-hydroxycitric acid, and related compositions thereof |
| 01/14/2004 | EP1379260A2 Methods for treating the inflammatory component of a brain disorder |
| 01/14/2004 | EP1379257A2 Prodrugs of anticancer agents employing substituted aromatic acids |
| 01/14/2004 | EP1379252A2 Nociceptin analogs |
| 01/14/2004 | EP1379249A1 Fused cyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function |
| 01/14/2004 | EP1379246A1 Nociceptin analogs |
| 01/14/2004 | EP1379239A2 N-(2-arylethyl) benzylamines as antagonists of the 5-ht6 receptor |
| 01/14/2004 | EP1379237A2 Pyrrolidine sulfonamides |
| 01/14/2004 | EP1379236A1 Treatment of tics, tremors and related disorders |
| 01/14/2004 | EP1379235A2 Compositions and methods for enhancing paracellular permeability across epithelial and endothelial barriers |
| 01/14/2004 | EP1379231A2 Pharmacologically active strong acid solutions |
| 01/14/2004 | EP1379222A1 Orodispersible effervescent tablets |
| 01/14/2004 | EP1379221A2 Pharmaceutical product with reticulated crystalline microstructure |
| 01/14/2004 | EP1379125A1 Transgenic animals expressing antibodies specific for genes of interest and uses thereof |
| 01/14/2004 | EP1265882B1 Method for the preparation of citalopram |
| 01/14/2004 | EP1189900B1 Heterocyclic aminopyrrolidine derivatives as melatonergic agents |
| 01/14/2004 | EP1115404B1 Use of prostanoid antagonists for the treatment of primary headache disorders |
| 01/14/2004 | EP1095018B1 Aminoiminoquinone and aminoquinone alkaloid compounds as caspase inhibitors |
| 01/14/2004 | EP1056448B1 Pharmaceutical combinations containing tramadol |
| 01/14/2004 | EP1006802A4 Chemical and pharmacological standardization of herbal extracts |
| 01/14/2004 | EP0975761B1 Recombinant human beta interferon with enhanced solubility |
| 01/14/2004 | EP0832091B1 C-4' modified adenosine kinase inhibitors |
| 01/14/2004 | CN1468309A Anti-il-12 antibodies, compositions, methods and uses |
| 01/14/2004 | CN1468307A Anti-dual integrin antibodies, compositions, methods and uses |
| 01/14/2004 | CN1468305A Modulation of the transcription of pro-inflammatory gene products |
| 01/14/2004 | CN1468302A Gsk3 polypeptides |
| 01/14/2004 | CN1468249A Methods and compositions for treating flaviviruses and pestiviruses |
| 01/14/2004 | CN1468247A Ethers of 7-desmethylrapamycin |